{"product_id":"discovery-pestle-analysis","title":"Discovery PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock strategic clarity with our PESTLE Analysis of Discovery—three expert-level insights into political, economic, social, technological, legal and environmental forces shaping the company. Perfect for investors, consultants and strategists, it’s ready-to-use and editable. Buy the full report now for the complete, actionable breakdown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSouth Africa NHI and health policy direction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNHI legislation and public–private reforms could reshape risk pools, compress pricing and reconfigure provider networks, affecting private cover that serves approximately 16% of the population (~9 million) and a health sector spending near 8–9% of GDP. For Discovery this pressures medical-scheme administration fees, hospital and clinician contracts and claims management. Scenarios range from phased rollout to rapid shifts, creating implementation uncertainty and timing risk. Expect increased lobbying, compliance spend and product redesign to align with new contracting and reimbursement models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUK health policy and regulator stance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUK health policy and regulator stance reshapes PMI and wellness: NHS England's 2024\/25 budget of about £192bn and a waiting list exceeding 7.5m sustain demand for PMI and cash plans, with private cover reaching roughly 10% of the population. FCA Consumer Duty (effective July 2023) and PRA expectations on conduct and fair value increase compliance costs and product governance requirements. Political shifts affecting NHS procurement or vertical integration could expand or constrain partnership and outsourcing opportunities for insurers and providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment incentives for wellness and prevention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTax incentives and subsidies that lower costs for screenings, vaccinations and fitness programs can raise preventive uptake; WHO reports NCDs cause ~41 million deaths annually (71% of deaths, 2021). Discovery’s shared-value Vitality model, active across 24 markets as of 2024, links rewards to behavior to improve adherence and reduce claims. Public–private partnerships can scale screening and lifestyle programs to cut NCD burden, but success hinges on alignment with budget cycles and rising political appetite for prevention-led savings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical risk and market entry approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitical risk, sanctions and licensing materially shape Discovery’s international expansion: FDA median review ~10 months and EMA centralized review ~210 days set baselines, while 194 WHO member states have divergent regimes; 2024 saw over 30 national elections increasing policy reversal risk, requiring active engagement with regulators and health ministries and contingency plans for sudden regulatory shifts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory timelines: FDA 10m, EMA 210d\u003c\/li\u003e\n\u003cli\u003eGlobal scope: 194 WHO states\u003c\/li\u003e\n\u003cli\u003ePolitical volatility: 30+ elections in 2024\u003c\/li\u003e\n\u003cli\u003eMitigation: regulator\/health ministry engagement, contingency planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFX controls and fiscal policy in core markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSouth African exchange controls (R1m annual discretionary allowance), corporate tax 27% and VAT 15%, plus a 5yr CDS ~350bps and 10y bond ~10.5% (mid‑2025), constrain capital mobility and increase dividend repatriation\/friction; sovereign risk raises hedging costs and repatriation timing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFiscal tightening: lowers affordability, cuts discretionary spend\u003c\/li\u003e\n\u003cli\u003eStimulus: boosts consumption, raises short‑term demand\u003c\/li\u003e\n\u003cli\u003eSin taxes: raise prices, reduce consumption, may improve public health\u003c\/li\u003e\n\u003cli\u003eTreasury: stress tests, pre‑funding, FX hedges, capital planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNHI reforms, NHS pressure, regulatory delays and SA capital controls risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNHI reforms, UK NHS pressures and global regulatory timelines (FDA 10m, EMA 210d) create implementation, compliance and contracting risk for Discovery; private cover ~16% (~9m) and health spend ~8–9% GDP amplify market impact. Geopolitical volatility (30+ elections 2024) and SA capital controls (R1m allowance, corp tax 27%, VAT 15%) raise expansion and repatriation costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate cover (SA)\u003c\/td\u003e\n\u003ctd\u003e16% (~9m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNHS budget 24\/25\u003c\/td\u003e\n\u003ctd\u003e£192bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA\/EMA\u003c\/td\u003e\n\u003ctd\u003e10m \/ 210d\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSA tax\/controls\u003c\/td\u003e\n\u003ctd\u003eCorp 27% VAT 15% R1m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental and Legal forces uniquely impact Discovery, with data-backed trends and forward-looking insights to help executives, consultants, and investors identify risks, opportunities, and strategy implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Discovery that streamlines stakeholder alignment and meeting prep and can be dropped into slides or reports; editable notes let teams tailor insights to region or business line for faster decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer income and affordability cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsumer income cycles shape lapse rates and product mix: IMF WEO 2025 shows 2024 GDP growth of ~0.8% in South Africa, ~0.3% in the UK and ~3.5% in other EMs, while CPI averaged ~5.8% (SARB) in SA and ~3% (ONS) in the UK, squeezing disposable income and increasing lapses in mid\/low-tier products. Scenario models calibrated to 2024 real-wage moves (UK real wages ~+2% y\/y; SA stagnation) imply ~0.8 percentage-point rise in lapse rates per -1% real-wage fall and ~0.5–1.2% premium sensitivity, reducing Vitality engagement ~0.6% per -1% real wage; this dictates prioritising flexible pricing and broker\/direct digital push where elasticity is highest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical inflation and claims trajectory\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSouth African medical inflation ran near 8–9% in 2024 versus general CPI about 5–6%, lifting Discovery Health loss ratios; utilization rose as elective procedures rebounded ~15% post‑COVID while chronic disease (diabetes\/hypertension) prevalence remains elevated (~10–12% adults). Provider tariff negotiations and benefit design levers (formularies, co‑pays) are key; stress tests show a 6–8ppt claims shock could erode margins ~2–3ppt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and investment returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInterest rate levels drive investment income and set reserving discount rates—US 10‑yr at ~4.2% (June 2025) lifts asset yields and reduces PV of liabilities, improving solvency coverage. Balance sheet duration matching and asset allocation must extend duration into corporates and long govies to hedge liability curves and reduce capital volatility. Guaranteed products and annuities face margin pressure; stress tests assuming a 100 bps cut or a 50–150 bps parallel yield‑curve shift model reserve increases and capital strain. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmployment trends and group benefits demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising unemployment in South Africa (≈33% in 2024) depresses corporate scheme membership and premium volumes as SME take-up falls faster than large corporates; large employers retain group schemes, supporting stable premium pools while SMEs shift to cost‑saving flexible benefits. Wage bills rose ~6% y\/y in 2024, driving demand for benefits that control total rewards; employers report wellness programmes deliver ROI in the region of 3:1 to 6:1. Pipeline scenarios: tight labour markets boost uptake and premium growth 3–7% annually; weak labour markets shift volumes toward scaled, modular offerings.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEmployment impact: high unemployment → lower SME membership, stable large-corp retention\u003c\/li\u003e\n\u003cli\u003eWage pressure: ~6% wage growth → demand for cost-effective benefits\u003c\/li\u003e\n\u003cli\u003eWellness ROI: 3:1–6:1 supports employer investment\u003c\/li\u003e\n\u003cli\u003eForecast: tight market +3–7% premiums; weak market → modular SME offerings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency volatility and translation risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCurrency moves in ZAR and GBP materially affect Discovery’s reported rand revenues and capital when translating UK earnings and dollar-priced tech costs; USD\/ZAR around 18.5 and GBP\/ZAR ~23.5 (mid-2025) amplify translation losses on a weaker ZAR.\u003c\/p\u003e\n\u003cp\u003eHedging policies use forwards and natural offsets from UK liabilities and local underwriting; procurement in hard currency raises operating cost exposure for tech and reinsurers.\u003c\/p\u003e\n\u003cp\u003eScenario: sustained 20% ZAR depreciation would reduce reported rand equity and inflate imported tech costs materially; volatility spikes increase hedging costs and earnings variance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTranslation risk: high\u003c\/li\u003e\n\u003cli\u003eHedging: active forwards\u003c\/li\u003e\n\u003cli\u003eHard-currency procurement: significant\u003c\/li\u003e\n\u003cli\u003e20% ZAR fall: material P\u0026amp;L\/equity impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNHI reforms, NHS pressure, regulatory delays and SA capital controls risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroeconomic squeeze: 2024 GDP growth ~0.8% (ZA), ~0.3% (UK) with CPI ~5.8% (ZA) and ~3% (UK) reducing real incomes and raising lapses; calibrated models show ~0.8ppt lapse rise per -1% real‑wage fall. Medical inflation ~8–9% in 2024, lifting loss ratios; SA unemployment ~33% cuts SME scheme volumes. FX and rates: USD\/ZAR ~18.5, GBP\/ZAR ~23.5 (mid‑2025); US 10yr ~4.2%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSA GDP growth (2024)\u003c\/td\u003e\n\u003ctd\u003e~0.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK GDP (2024)\u003c\/td\u003e\n\u003ctd\u003e~0.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPI SA\/UK\u003c\/td\u003e\n\u003ctd\u003e5.8% \/ 3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical inflation (SA 2024)\u003c\/td\u003e\n\u003ctd\u003e8–9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnemployment SA (2024)\u003c\/td\u003e\n\u003ctd\u003e≈33%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/ZAR (mid‑2025)\u003c\/td\u003e\n\u003ctd\u003e~18.5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS 10yr (Jun‑2025)\u003c\/td\u003e\n\u003ctd\u003e~4.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eDiscovery PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Discovery PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use. What you see is the final file with no placeholders or teasers. After checkout you’ll be able to download this exact document immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162705375609,"sku":"discovery-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/discovery-pestle-analysis.png?v=1762707129","url":"https:\/\/portersfiveforce.com\/products\/discovery-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}